Palvella Therapeutics, Inc. (PVLA)Healthcare | Biotechnology | Wayne, United States | NasdaqGM
130.90 USD
-3.48
(-2.590%) ⇩
(Oct. 13, 2026, 12:39 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:12 a.m. EDT
Palvella presents a classic high-risk biotech profile with no earnings yet, weighed down by a nine-year price decline of over 50 percent. However, the company holds a fortress-like balance sheet with minimal debt and ample cash reserves, fueling a recent aggressive price recovery that has reclaimed ground above the 200-day moving average. While the 50-day average remains a resistance hurdle, the options market is pricing in substantial upside volatility, suggesting traders anticipate a catalyst. Investors should view this as a speculative hold rather than a core investment, given the lack of profitability and the sector's inherent binary risks. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.043542 |
| AutoETS | 0.053216 |
| AutoARIMA | 0.072068 |
| MSTL | 0.077772 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 3.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.276 |
| Excess Kurtosis | 0.83 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.441 |
| Market Cap | 1,886,060,416 |
| Forward P/E | -16.15 |
| Website | https://palvellatx.com |
As of Oct. 10, 2026, 5:12 a.m. EDT: Speculators are positioning for significant upside potential, evidenced by heavy open interest in out-of-the-money calls at the 170 strike compared to put activity. Implied volatility remains elevated, indicating expectations of a binary event or high price swings.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.82780194 |
| Address1 | 353 W. Lancaster Avenue |
| Address2 | Suite 200 |
| All Time High | 780.0 |
| All Time Low | 6.2 |
| Ask | 195.41 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 236,130 |
| Average Daily Volume3 Month | 210,773 |
| Average Volume | 210,773 |
| Average Volume10Days | 236,130 |
| Bid | 111.17 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 15.065 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 130.9 |
| Current Ratio | 21.179 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 134.14 |
| Day Low | 129.97 |
| Debt To Equity | 10.441 |
| Display Name | Palvella Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,846,600 |
| Earnings Call Timestamp Start | 1,785,846,600 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 1,708,259,712 |
| Eps Current Year | -6.42167 |
| Eps Forward | -8.107 |
| Eps Trailing Twelve Months | -4.85 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 147.5296 |
| Fifty Day Average Change | -16.629608 |
| Fifty Day Average Change Percent | -0.11272048 |
| Fifty Two Week Change Percent | 82.7802 |
| Fifty Two Week High | 161.38 |
| Fifty Two Week High Change | -30.480011 |
| Fifty Two Week High Change Percent | -0.18887106 |
| Fifty Two Week Low | 68.96 |
| Fifty Two Week Low Change | 61.939995 |
| Fifty Two Week Low Change Percent | 0.89820176 |
| Fifty Two Week Range | 68.96 - 161.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,420,209,000,000 |
| Float Shares | 10,659,772 |
| Forward Eps | -8.107 |
| Forward P E | -16.146538 |
| Free Cashflow | -25,446,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 29 |
| Fullday Change | -3.480011 |
| Fullday Change Percent | -2.5896792 |
| Fullday Price | 130.9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11595 |
| Held Percent Institutions | 1.03834 |
| Implied Shares Outstanding | 14,408,407 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,713,830,400 |
| Last Split Factor | 1:80 |
| Long Business Summary | Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania. |
| Long Name | Palvella Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,886,060,416 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_534271315 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -61,696,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,153,768,678 |
| Number Of Analyst Opinions | 15 |
| Open | 134.08 |
| Operating Cashflow | -36,513,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 484 253 1461 |
| Previous Close | 134.38 |
| Price Eps Current Year | -20.384106 |
| Price Hint | 2 |
| Price To Book | 8.689014 |
| Profit Margins | 0.0 |
| Quick Ratio | 21.008 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -3.480011 |
| Regular Market Change Percent | -2.5896792 |
| Regular Market Day High | 134.14 |
| Regular Market Day Low | 129.97 |
| Regular Market Day Range | 129.97 - 134.14 |
| Regular Market Open | 134.08 |
| Regular Market Previous Close | 134.38 |
| Regular Market Price | 130.9 |
| Regular Market Time | 1,791,909,546 |
| Regular Market Volume | 91,343 |
| Return On Assets | -0.22055 |
| Return On Equity | -0.46625 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 14,408,407 |
| Shares Percent Shares Out | 0.1752 |
| Shares Short | 2,524,140 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,291,288 |
| Short Name | Palvella Therapeutics, Inc. |
| Short Percent Of Float | 0.1982 |
| Short Ratio | 11.77 |
| Source Interval | 15 |
| State | PA |
| Symbol | PVLA |
| Target High Price | 267.0 |
| Target Low Price | 205.0 |
| Target Mean Price | 228.93333 |
| Target Median Price | 232.0 |
| Total Cash | 250,584,000 |
| Total Cash Per Share | 17.392 |
| Total Debt | 22,642,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 124.7617 |
| Two Hundred Day Average Change | 6.1382904 |
| Two Hundred Day Average Change Percent | 0.049200118 |
| Type Disp | Equity |
| Volume | 91,343 |
| Website | https://palvellatx.com |
| Zip | 19,087 |